scout
|Videos|March 28, 2017

Alternative Sunitinib Scheduling for mRCC

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME